SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

RaveDAO is a global community uniting music, technology, and purpose. Since their first sold-out event at Dubai 2024, they have expanded across Europe, the Middle East, North America, and Asia, hosting world-class experiences with over 100,000 total attendees and 3,000+ attendees for each event.  RaveDAO has worked with top-tier artists like Vintage Culture, Don Diablo, Chris Avantgarde, Lilly Palmer, MORTEN, Bassjackers, and GENESI and has support from Binance, OKX, Bitget, and Polygon. RaveDAO is redefining live entertainment in Web3 and has active partnerships with 1001Tracklists, AMF, and Warner Music.  Beyond the dance floor, RaveDAO channels energy and attention toward impact. In 2025 alone, proceeds from its events helped restore sight to 400+ cataract patients in Nepal and fund over 150 meditation programs across the U.S.

RaveDAO

RaveDAO is experiencing significant momentum driven by high trading volume, whale accumulation, and speculation surrounding potential major corporate partnerships. Community sentiment remains highly divided, with many traders riding the volatility of the recent price surge while others express skepticism regarding potential supply releases and the sustainability of the current rally.

Keeta is a high-performance layer-1 blockchain designed to unify transactions across different blockchains and fiat payment systems, eliminating the need for costly intermediaries, reducing fees, and enabling near-instant settlements. With 400-millisecond transaction finality and the ability to process 10 million transactions per second, Keeta sets a new industry benchmark for speed and scalability.  Founded in 2022 and backed by Eric Schmidt, the former CEO of Google, Keeta has been engineered to meet the stringent regulatory and operational requirements of financial institutions. Its advanced on-chain compliance protocols, including KYC and AML, ensure security and regulatory adherence. Keeta’s architecture natively supports asset tokenization and digital identity, making it an ideal platform for stablecoins and real-world asset transfers.  By facilitating cross-chain transactions and interoperability with existing payment systems, Keeta bridges the gap between cryptocurrencies and fiat, enabling a secure, efficient, and compliant global financial ecosystem.

Keeta

Keeta (KTA) is currently seeing significant community activity as investors weigh recent reports of a bank acquisition and ongoing speculation regarding potential institutional partnerships. While some traders are expressing frustration over price volatility and volume, others are actively accumulating based on the project's high-speed blockchain claims and its potential role in future financial infrastructure.

Astera Labs, Inc. is a global semiconductor company, which engages in the provision of hardware and software solutions for AI and cloud infrastructure applications to solve data, memory, and networking bottlenecks. It operates through the following geographical segments: Taiwan, China, United States, and Other. The company was founded by Jitendra Mohan, Casey Morrison, and Sanjay Gajendra in October 2017 and headquartered in San Jose, CA.

Astera Labs Inc.

Astera Labs Inc

Astera Labs is facing intense volatility as the stock undergoes a sharp correction, triggering heavy debate among traders about whether the current price levels represent a significant buying opportunity or a deeper valuation trap. While some market participants are focused on potential institutional accumulation and long-term infrastructure demand, others are wary of the aggressive insider selling and recent technical breakdowns that have eroded confidence.

PENGU is the official coin of Pudgy Penguins.  Pudgy Penguins has become the face of crypto with one of the most influential communities in the industry. From large companies wearing the Penguin, to being featured in ETF commercials, to garnering millions of followers and over 100 billion views, the Pengu has become a cultural icon making PENGU the world’s social currency.  PENGU allows for the ever-expanding Pudgy Penguin fanbase and the hundreds of millions of people outside of crypto that see and share the Pudgy Penguin everyday, to join The Huddle. PENGU is a symbol for community, memes, and good vibes.  Believe in Pengu. Believe in the Prophecy.

Pudgy Penguins

Pudgy Penguins is trending as holders discuss its transition from a niche digital asset into a 'phygital' powerhouse, highlighted by widespread retail presence in major stores and the recent launch of a Visa-backed spending card. The community is actively debating the project's long-term utility and potential for price momentum, with many investors using current market fluctuations as a buying opportunity to DCA into their positions.

Tilray Brands, Inc. engages as a consumer packaged goods company, which focuses on medical cannabis research and the cultivation, processing, and distribution of cannabis products worldwide. It operates through the followings segments: Cannabis, Distribution, Beverage, and Wellness. The Cannabis segment focuses on cultivation, production, distribution, and sale of both medical and adult-use cannabis products. The Distribution segment is involved in purchase, resale, and distribution of pharmaceutical and wellness products. The Beverage segment refers to the production, marketing, and sale of beverages. The Wellness segment represents the production, marketing, and distribution of hemp-based food and other wellness products. The company was founded on January 24, 2018 and is headquartered in Leamington, Canada.

Tilray Brands Inc

Tilray Brands is attracting heavy investor attention as the company navigates a complex turnaround, with the community closely tracking potential Schedule III rescheduling catalysts and the impact of the new Medicare CBD pilot program. While some shareholders express frustration over past management decisions and performance, many are actively monitoring the stock for a trend reversal, heavily debating the timing of regulatory milestones versus ongoing sector volatility.

NANO Nuclear Energy, Inc. is a microreactor and nuclear technology company, which provides supply energy services. Its products in technical development are ZEUS, a solid core battery reactor, and ODIN, a low-pressure coolant reactor. The company is founded by Jiang Yu in February, 2022 and is headquartered in New York, NY.

Nano Nuclear Energy Inc.

Nano Nuclear Energy is trending as investors react to a series of strategic milestones, including a new feasibility study for a major Texas power hub and the continued expansion of its microreactor development pipeline. The community is actively debating the company's long-term commercialization timeline and the broader role of advanced nuclear technology in meeting the surging electricity demands of AI data centers.

Terrestrial Energy, Inc. is an advanced nuclear technology company focused on next-generation nuclear energy systems. The company is developing the Integral Molten Salt Reactor (IMSR), an innovative type of Generation IV molten salt reactor designed to produce reliable, low-carbon heat and electricity at competitive costs. The company is headquartered in Charlotte, NC.

Terrestrial Energy Inc.

IMSR is trending as investors react to the companys dual Other Transaction Agreements with the U.S. Department of Energy, which aim to accelerate the commercialization of its integral molten salt reactor technology. Community discussions are heavily focused on the stock's potential for a significant valuation rerating as it gains federal support, with bulls drawing comparisons to the market trajectory of established sector peers while debating the company's timeline for achieving reactor criticality.

Bank of America Corp. is a bank and financial holding company, which engages in the provision of banking and nonbank financial services. It operates through the following segments: Consumer Banking, Global Wealth and Investment Management (GWIM), Global Banking, Global Markets, and All Other. The Consumer Banking segment offers credit, banking, and investment products and services to consumers and small businesses. The GWIM segment focuses on solutions to meet clients’ needs through a full set of investment management, brokerage, banking, and retirement products. The Global Banking segment deals with lending-related products and services, integrated working capital management and treasury solutions to clients, and underwriting and advisory services. The Global Markets segment includes sales and trading services, as well as research, to institutional clients across fixed-income, credit, currency, commodity, and equity businesses. The All Other segment consists of asset and liability management activities, equity investments, non-core mortgage loans and servicing activities, the net impact of periodic revisions to the mortgage servicing rights valuation model for both core and non-core MSRs, other liquidating businesses, residual expense allocations and other. The company was founded by Amadeo Peter Giannini in 1904 and is headquartered in Charlotte, NC.

Bank Of America Corp.

Bank of America Corp

Bank of America is under pressure following fourth-quarter earnings that, despite beating consensus estimates, failed to satisfy investor expectations amidst ongoing market volatility. The community is actively discussing the broader banking sector's sensitivity to potential regulatory credit card interest rate caps and shifting economic conditions as traders navigate the fallout from mixed earnings reports across the financial space.

Intuitive Machines, Inc. is a space exploration, infrastructure, and services company, which engages in contributing to the establishment of cislunar infrastructure and helping to develop cislunar and deep space commerce. It offers space products and services. The company was founded by Stephen J. Altemus, Kam Ghaffarian, and Timothy P. Crain in 2013 and is headquartered in Houston, TX.

Intuitive Machines Inc - Ordinary Shares - Class A

Intuitive Machines Inc

Intuitive Machines is trending as the successful Artemis II mission fuels massive investor enthusiasm for the space infrastructure sector, with the community closely tracking the stock's momentum following significant contract-related developments. Traders are actively debating whether this represents a sustainable long-term breakout or a temporary rally, while excitement builds around the company's expanding role in lunar exploration and upcoming mission milestones.

Ares Capital Corp is a traded fund invests in companies located in the United States and Canada with an EBITDA of USD 10 - 250 million. The fund targets companies operating in the fields of health care services, software & services, consumer durables & apparel, energy, food & beverage and retail. It provides financing in the form of debt and equity for mezzanine, buyouts, acquisitions, recapitalizations, restructurings, rescue financing, growth capital and general refinancing with an investment size ranging from USD 10 - 500 million. The fund acquires controlling Interest. It acts as lead investor and takes a seat on the board of directors.

Ares Capital Corp

Ares Capital Corporation

Ares Capital is currently attracting significant attention as investors weigh the stability of its long-standing dividend track record against broader concerns surrounding the private credit sector and potential borrower stress. While some community members view the current share price as a bargain and are actively accumulating shares to capture high yields, others express caution, citing macroeconomic volatility and the risks associated with high exposure to complex loan structures like PIK interest.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

LLY Launches GLP-1 Pill, Expands Access Through Pharmacy Partnerships

Eli Lilly launches oral GLP-1 pill Foundayo, pairing low-cost access with Amazon and GoodRx partnerships to challenge rivals in the fast-growing obesity market.

Viking Therapeutics to Participate at Upcoming Investor Conferences

Viking Therapeutics to Participate at Upcoming Investor Conferences Viking Therapeutics to Participate at Upcoming Investor Conferences PR Newswire SAN DIEGO, April 10, 2026 SAN DIEGO, April 10, 2026...

MH & Associates Securities Management Corp ADV Buys New Stake in Viking Therapeutics, Inc. $VKTX

MH & Associates Securities Management Corp ADV bought a new stake in Viking Therapeutics, Inc. (NASDAQ:VKTX - Free Report) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 43,634 shares of the biotechnology company's...

Viking Therapeutics, Inc. (VKTX) Stock Dips While Market Gains: Key Facts

The latest trading day saw Viking Therapeutics, Inc. (VKTX) settling at $33.93, representing a -2.5% change from its previous close.

How to Play Lilly Stock Post Oral Obesity Pill Foundayo's Approval

LLY wins FDA nod for oral obesity pill Foundayo, boosting shares as it eyes billions in sales and a fast catch-up to rivals in the booming GLP-1 market.

Where Will Viking Therapeutics Stock Be in 10 Years?

Key PointsViking Therapeutics has a shot at becoming a leader in the weight-loss market...

LLY Stock Up on GLP-1 Pill Approval: Can it Outpace NVO's Wegovy Pill?

Eli Lilly stock gains on FDA nod for oral obesity drug Foundayo, expanding its portfolio and patient access, setting up a fresh showdown with Novo Nordisk in the GLP-1 market.

Viking Therapeutics, Inc. (NASDAQ:VKTX) Given Average Recommendation of "Moderate Buy" by Brokerages

Shares of Viking Therapeutics, Inc. (NASDAQ:VKTX - Get Free Report) have been given a consensus recommendation of "Moderate Buy" by the fourteen research firms that are covering the firm, Marketbeat reports. One research analyst has rated the stock with a sell rating, four have assigned a hold ra...

<ul class="summary-bullets"><li>CNBC traders said acquisitions are becoming a primary route for drugmakers to enter advanced weight-loss therapy pipelines.</li><li>One trader called it “almost a foregone conclusion” that Viking and Structure could be acquired this year.</li><li>Investor attention remains focused on VK2735, Viking’s dual-agonist obesity therapy advancing through Phase 3 trials.</li></ul>Shares of Viking Therapeutics, Inc. (VKTX) rose over 2% in extended trading on Wednesday after CNBC’s Fast Money said the company could be acquired this year as drugmakers race to expand their presence in the booming GLP-1 obesity market.<a href="https://stocktwits.com/symbol/VKTX">VKTX stock</a> jumped over 1% on Wednesday, marking its second consecutive session of gains.<h2 class="st-heading-2">CNBC Traders Flag Viking As Buyout Target</h2>During the show, traders said pharma companies are turning to acquisitions to secure exposure to advanced weight-loss therapies rather than relying only on internal development.“How do we get in the game? We have to make an acquisition,” one trader said, pointing to Structure Therapeutics (GPCR) and Viking as potential targets and adding, “I think it’s almost a foregone conclusion that those two names at some point get acquired this year.” Viking was also mentioned among CNBC’s Final Trade selections alongside Burlington Stores, Nike, and the S&amp;P 500.<h2 class="st-heading-2">Viking Gains Attention In GLP-1 Deal Wave</h2>Interest in obesity-focused drug developers has intensified following recent momentum across the sector after Eli Lilly secured U.S. approval for its once-daily weight-loss pill Foundayo, just months after Novo Nordisk launched the first oral GLP-1 obesity pill earlier this year.“It just seems like this is an enormous opportunity that is not a lot of money for a big cap pharma or even a medium cap pharma,” one trader on Fast Money said. Recent dealmaking in the market&nbsp;supports their view. Pharma companies have increasingly focused on smaller pipeline acquisitions rather than large megadeals.&nbsp;On Tuesday, Eli Lilly said it will acquire Centessa Pharmaceuticals in a deal valued at up to $7.8 billion. Similar transactions include Biogen acquiring Apellis Pharmaceuticals for $5.6 billion upfront and Merck acquiring Terns Pharmaceuticals for about $5.7 billion.<h2 class="st-heading-2">Viking Expands Obesity Drug Pipeline</h2>Investor focus on Viking has centered on its experimental obesity therapy VK2735, a dual agonist being developed in both injectable and oral formulations. The company recently said enrollment is underway in a late-stage clinical trial evaluating the injectable version of VK2735 in about 1,000 patients with type 2 diabetes who are overweight or obese, with the primary endpoint measuring percentage change in body weight after 78 weeks of treatment compared with placebo.The company expects to have four Phase 3 trials underway this year evaluating VK2735 and plans to advance the oral formulation into late-stage testing following discussions with the U.S. Food and Drug Administration (FDA).Beyond VK2735, Viking is also advancing a separate obesity therapy targeting the amylin pathway, with plans to file an investigational new drug application this quarter and begin early-stage human testing.&nbsp;The drugmaker said earlier this month that&nbsp;it does not need&nbsp;a&nbsp;dominant market share to succeed despite competition from larger pharmaceutical players. “We don't need to get 30% market share,” the company said. “We need to get 5% to 10% share, and we're extremely successful.”<h2 class="st-heading-2">How Do Retail Traders Feel About VKTX?</h2>On Stocktwits, retail sentiment for VKTX has jumped to ‘neutral’ from ‘bullish’ levels a day ago amid a 1,155% surge in message volumes over the past quarter. Watchers have also increased 20% in a year.<figure class="image"><img src="https://news.stocktwits-cdn.com/vktx_ss_png_172d01a9fd.webp" alt="vktx ss.png" width="967" height="143"><figcaption>VKTX sentiment and message volume as of April 2 | Source: Stocktwits</figcaption></figure>One user&nbsp;<a href="https://stocktwits.com/wealthengine6/message/649252701">called</a> VK2735 as the “Next blockbuster oral obesity drug? Likely ahead of $GPCR.”<stembedurl>https://stocktwits.com/wealthengine6/message/649252701</stembedurl>Another user&nbsp;<a href="https://stocktwits.com/507Trader/message/649230524">floated</a> the idea of a possible takeover by AbbVie, saying, “Come on AbbVie, one share of yours for each share of ours and call it a day.”<stembedurl>https://stocktwits.com/507Trader/message/649230524</stembedurl>VKTX stock has risen 38% over the past year.For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/tesla-stock-dips-overnight-us-demand-weakness-ahead-of-q1-deliveries/cZ7xWlERIF8">Tesla Stock Dips Overnight: US Demand Signals Weakness Ahead Of Closely Watched Q1 Delivery Print</a>

In this photo illustration, a smartphone displays the logo of Viking Therapeutics, Inc., in front of a screen showing the company's latest stock market chart on July 19, 2025 in Chongqing, China. (Photo illustration by Cheng Xin/Getty Images)

VKTX Stock Rises After-Hours: CNBC Flags Viking As Likely Buyout Target This Year As Big Pharma Hunts Next GLP-1 Winner

Viking was also highlighted among CNBC’s Final Trade selections alongside Burlington Stores, Nike and the S&P 500.

Equity

Here's How Much $100 Invested In Viking Therapeutics 10 Years Ago Would Be Worth Today

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

Fiscal Period	Estimated	Reported	Surprise	Result
Q1 '26	-$1.02	--	--	N/A
Q4 '25	-$0.90	-$1.38	-53.80%	MISSED
Q3 '25	-$0.70	-$0.81	-15.17%	MISSED
Q2 '25	-$0.45	-$0.58	-29.90%	MISSED
Q1 '25	-$0.33	-$0.41	-25.00%	MISSED

VKTX
Viking Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q1 '26

Historical Earnings

Latest VKTX News

VKTXViking Therapeutics Inc